Tag Archives: TherapeuticsMD

A Director at TherapeuticsMD (NASDAQ: TXMD) is Buying Shares

Today, a Director at TherapeuticsMD (TXMD – Research Report), Cooper Collins, bought shares of TXMD for $99.6K. This recent transaction increases Cooper Collins’ holding in the company by 83.33% to a total of $218.5K. In addition to Cooper Collins, one

Oppenheimer Sticks to Their Buy Rating for TherapeuticsMD (TXMD)

Oppenheimer analyst Jay Olson reiterated a Buy rating on TherapeuticsMD (TXMD – Research Report) today and set a price target of $14. The company’s shares closed yesterday at $5.09. Olson noted: “TXMD reported 4Q results and launch progress for 2019

Oppenheimer Reaffirms Their Buy Rating on TherapeuticsMD (TXMD)

Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMD – Research Report) yesterday and set a price target of $14. The company’s shares closed on Friday at $5.23. Olson observed: “TXMD provided an update on the Imvexxy launch

TherapeuticsMD (TXMD) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMD – Research Report) yesterday and set a price target of $14. The company’s shares closed yesterday at $5.10. Olson said: “We met management for an update on Imvexxy launch

Cantor Fitzgerald Reiterates a Buy Rating on TherapeuticsMD (TXMD)

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on TherapeuticsMD (TXMD – Research Report) today and set a price target of $27. The company’s shares closed on Friday at $5.11. Chen observed: “We reiterate our OW rating. The execution

Analysts’ Top Healthcare Picks: TherapeuticsMD (TXMD), Heron Therapeutics (HRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TherapeuticsMD (TXMD – Research Report), Heron Therapeutics (HRTX – Research Report) and Immunomedics (IMMU – Research Report) with bullish sentiments. TherapeuticsMD (TXMD)